For today’s life sciences companies, outdated operating models are hindering transformation initiatives as well as impeding growth and the ability to keep pace with customer and marketplace demands. The constant friction is making processes cumbersome and operations costly.
Cognizant can help. Our Life Sciences Business Process Services (BPS) practice helps pharmaceutical, biotech, medical device and generics providers bring their products to market faster, reduce the costs of drug development and decrease cycle times.
From human science to automation, industry leaders choose us to help them accelerate the shift to digital for better health outcomes. Whether driving process improvements to clinical operations, increasing sales effectiveness or enhancing drug safety, Cognizant is redefining the way you can benefit from global services.
Everest named Cognizant a leader and a Star Performer in RCM Business Process Services. The report recognizes Cognizant's wide array of technology tools that help in billing, denials management, coding and other functions within revenue cycle management.READ THE REPORT
of the world’s top 30 global pharmaceutical firms
of the world’s top 10 biotech companies
of the world’s top 15 medical device companies
With a deep understanding of today’s life sciences industry, we offer business process services to make you more effective, efficient and virtualized. The result: You’ll be able to streamline and effectively manage costs, customer support and service operations—and redirect internal business resources toward more strategic, value-added projects.
Our clinical data management services offer proven and mature data management processes with built-in transition, quality control and assurance. Leveraging technology and analytics, we provide process automation, continuous process improvement and robust, scalable data management platform services. And we help achieve faster access to information by reducing database lock time by 30%.
Our services include:
Increased drug safety stringency is driving life sciences organizations to embrace a proactive pharmacovigilance (PV) strategy—aggressively adopting measures to detect and manage emerging safety risks. At the same time, they’re facing key challenges to ensure regulatory compliance and reduced costs.
Cognizant’s PV center of excellence (CoE) can help you identify and execute an appropriate PV strategy. Our comprehensive set of solutions is based on our extensive experience in drug safety process consulting, IT solutions implementation and PV process outsourcing to reduce regulatory and business risks.
We’re uniquely positioned to help global drug safety and PV organizations perform better, through:
Increased drug safety regulatory guidelines covering risk evaluation and mitigation strategies are leading to larger, longer and more complex clinical trials. As a result, global regulatory agencies require more clinical documents.
Cognizant’s medical writing and publishing team has deep experience and skill in summarizing and communicating results, and synthesizing and translating complex data analysis into coherent documents. We deliver a variety of medical writing and publishing services. Our team of doctors, life sciences post-graduates and PhDs has experience across all major therapeutic areas and global regulatory documents. They deliver clear, scientifically accurate documents that are fully compliant with regulatory requirements. Our publishing team uses leading tools such as ISI Toolbox, Liquent Insight and eCTD express.
Cognizant’s Life Sciences BPS practice offers innovative biostatistics and statistical programming services as a part of our clinical offering. Our services cover all aspects of the biostatistics value chain, from creating a statistical analysis plan through preparing a statistical methodology section in a clinical study report for submission to regulatory authorities.
We have extensive experience providing end-to-end biostatistical analysis and programming. Our uniquely networked global approach ensures metrics-driven delivery of clinical data processes from locations across the U.S., India, Europe, Argentina and China.
Revenue cycle management for medical device companies consumes more resources than ever, yet results are disappointing. Unrealized revenues from denied claims and underpayments are growing. Payers and regulators frequently change systems and submission requirements, leading to more denials. And with consumer-directed health plans, patient cost share amounts for devices are accelerating, but most companies don’t have the ability to efficiently calculate or collect these.
Outdated, inflexible revenue management systems make it difficult to pinpoint the causes of claim denials and prevent future problems. Cognizant Medical Devices Revenue Cycle Management takes a business outcomes-oriented approach to delivering revenue cycle management based on our proprietary Delivering Business Outcomes (DBO) Framework. DBO uses a measured approach to continuous improvements that links process metrics to business outcomes. With it, we modernize every aspect of the medical device cash-to-order value chain, from preauthorization approvals to claims submission to collecting patient co-pays.LEARN MORE
Stay on top of what’s happening across Cognizant.
Come out and meet us at these upcoming events.